Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study

Ähnliche Einträge

• The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin‐based chemoradiotherapy in patients with head and neck squamous cell carcinoma
  von: Anouk W. M. A. Schaeffers, et al.
  Veröffentlicht: (2024)
• Pretreatment fat‐free mass index correlates with early death in patients with head and neck squamous cell carcinoma
  von: Charbél Talani, et al.
  Veröffentlicht: (2024)
• Establishment of an in situ model to explore the tumor immune microenvironment in head and neck squamous cell carcinoma
  von: Congxian Lu, et al.
  Veröffentlicht: (2024)
• The impact of COVID‐19 and vaccination status on outcomes in veterans with head and neck squamous cell carcinoma
  von: James D. Johns, et al.
  Veröffentlicht: (2024)
• Survival and complications after carotid resection for head and neck squamous cell carcinoma: A systematic review and pooled analysis
  von: Gian Marco Pace, et al.
  Veröffentlicht: (2024)